Aug 21, 2024, 14:23
STORM trial results at ESTRO 24
ESTRO shared on X:
“STORM trial results on the treatment of pelvic nodal oligo-recurrence after Prostate Cancer, presented at ESTRO 24: ENRT improves biochemical and locoregional relapse-free survival rates compared with SBRT.”
Further information.
Source: ESTRO/X
Other posts Featuring ESTRO on OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 3, 2024, 11:53
Dec 3, 2024, 11:50
Dec 3, 2024, 11:43
Dec 3, 2024, 09:35